|
The
Food and Drug Administration (FDA) is warning health care professionals
that Strattera, a drug for attention deficit hyperactivity disorder
(ADHD) in adults and children, could cause severe liver injury in
patients. The warning, which is being added to Strattera labels
at the FDA's request, comes after two people faced liver damage
after taking the drug for several months.
More than 2 million people have used Strattera since it hit the
market in 2002. In past clinical trials involving 6,000 patients,
no signal for liver problems were reported.
The bolded warning indicates that, in a small percentage of patients,
severe liver injury may progress to liver failure resulting in death
or the need for a liver transplant. It's also noted that the
actual number of severe liver injury cases associated with Strattera
are unknown because of under-reporting of adverse events.
Patients who develop jaundice (yellowing of the skin or whites
of the eyes) or laboratory evidence of liver injury should stop
taking the medication, according to the warning.
Eli Lilly, Strattera's maker, plans
to alert health care professionals to the potential dangers of the
drug and is updating the package insert to include signs and symptoms
of liver problems. These include:
- Pruritus (Itchy skin)
- Jaundice
- Dark urine
- Upper right-sided abdominal tenderness
- Unexplained "flu-like" symptoms
Medical
News Today December 18, 2004
|